Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) — MG4101  

CD20-positive Non-Hodgkin Lymphoma Clinical Trial

Official title: Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Status Terminated

Clinical Trial Summary

Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials

Clinical Trial Description

Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has relapsed or refractory to prior chemotherapy or chemo-radiotherapy. ;

Related Conditions & MeSH terms

• CD20-positive Non-Hodgkin Lymphoma
• Lymphoma
• Lymphoma, Non-Hodgkin

• NCT number: NCT03578198
• Study type: Interventional
• Source: Seoul National University Hospital
• Status: Terminated
• Phase: Phase 2
• Start date: November 8, 2018
• Completion date: April 7, 2022